Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Gemcitabine + interferon gamma + Mitomycin C + Valrubicin|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Gemcitabine||Gemzar||Difluorodeoxycytidine Hydrochlorothiazide|LY-188011||Chemotherapy - Antimetabolite 11||Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary).|
|Mitomycin C||Mitozytrex||Chemotherapy - Alkylating 14||Mitomycin C is an antibiotic alkylating agent, which cross-links DNA to prevent DNA synthesis (NCI Drug Dictionary).|
|Valrubicin||Valstar||Antibiotic Ad 32|AD-32||Chemotherapy - Anthracycline 11 TOPO2 inhibitor 4||Valstar (valrubicin) is an anthracycline that is metabolized into compounds that inhibit topoisomerase II, resulting in inhibition of DNA synthesis and potentially leading to decreased tumor growth (PMID: 19145271, PMID: 20554745). Valstar (valrubicin) is FDA-approved for treatment of BCG-refractory urinary bladder carcinoma in situ (FDA.gov).|
|interferon gamma||Actimmune||gamma interferon|IFN-G|recombinant interferon gamma||Interferon gamma is a cytokine that binds IFN-gamma receptors, leading to pleiotropic effects, including stimulating antibody-dependent cytotoxicity and enhanced natural killer cell activity against tumor cells and the activation of caspases, leading to apoptosis of malignant cells (PMID: 14525967).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|